ANN ARBOR – The U.S. Meals and Drug Administration has granted accelerated approval to lecanemab for the remedy of Alzheimer’s illness. Research have proven promising organic results of clearing amyloid deposits within the mind that happen in Alzheimer’s illness.
The College of Michigan Well being has specialists speaking about early approval and what it means for the way forward for Alzheimer’s affected person care.
Judith HeidebrinkNeurologist and Medical Core Co-Lead, Alzheimer’s Illness Middle, Michigan
“Though lecanemab isn’t a treatment for Alzheimer’s illness, it might assist individuals with delicate signs of Alzheimer’s illness to stay unbiased for a very long time.” Due to this fact, as with all drug remedy, the dangers and advantages of particular person sufferers ought to be rigorously thought-about.Potential negative effects of lecanemab embody swelling of the mind and/or bleeding. This can require shut monitoring of anybody handled with lecanemab, together with MRI scans to search for negative effects.
“We do not know if lecanemab may help individuals with extra superior Alzheimer’s signs as a result of the research deal with early signs. However extra superior illness is more likely to profit.” There may be purpose to imagine that lecanemab can forestall signs of Alzheimer’s illness when administered to at-risk individuals? I’m thrilled to be taking part within the AHEAD 3-45 research.”
Henry PaulsonNeurologist and Director of Alzheimer’s Illness Middle, Michigan
“Alzheimer’s illness is a posh illness and lots of components are concerned in its development, one among which is amyloid,” he stated. “The delay of illness signs with lecanemab signifies that concentrating on amyloid is a viable therapeutic technique. It offers me hope.”